Business context and reporting period
Filing identity: The supplied filing is AzurRx BioPharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing identified as Gridai Technologies Corp. Confirm the issuer before relying on this summary.
AzurRx is a clinical-stage biotechnology company developing non-systemic treatments for gastrointestinal disorders. Its main candidate, MS1819-SD, targets exocrine pancreatic insufficiency; its beta-lactamase program is preclinical. The company reported no product sales or product revenue.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $2.12 million | $1.68 million; up $441,000 |
| General and administrative expense | $2.49 million | $1.92 million; up $569,000 |
| Operating loss | $4.60 million | $3.58 million |
| Net loss | $4.66 million | $3.63 million |
| Loss per share, basic and diluted | $0.26 | $0.29; weighted-average shares increased to 17.72 million from 12.45 million |
| Operating cash flow | $(2.63) million | $(2.21) million |
Margins are not meaningful because the company reported no revenue. At March 31, 2019, cash was $414,000, current assets were $2.80 million, current liabilities were $5.76 million, total liabilities were $6.24 million, and stockholders’ equity was $2.71 million. Management reported negative working capital of approximately $2.95 million and an accumulated deficit of approximately $52.18 million.
The balance sheet lists $1.73 million of current convertible debt; the debt note reports $1.70 million net of unamortized discount. The company also had a $161,000 note payable. The ADEC notes were issued for $2.0 million gross proceeds and bear 10% interest (reduced to 6% if both are repaid before December 31, 2019). They are secured by interests in expected French R&D tax credits and are convertible at ADEC’s option at $2.50 per share, subject to an ownership limit.
Material changes and unusual items
- Expenses and net loss increased year over year. Management attributed higher R&D expense to starting U.S. research operations and the OPTION study; higher G&A expense primarily reflected non-cash compensation tied to performance milestones.
- On March 27, 2019, AzurRx acquired all rights to MS1819-SD from Mayoly, ending their joint development and license agreement. Consideration included assumed liabilities, forgiveness of amounts owed by Mayoly, shares issued at signing, and further cash and share payments scheduled for 2019 and 2020. Mayoly retained an exclusive royalty-bearing right to revenue in certain territories.
- In February, the company raised $2.0 million from ADEC, a related party controlled by a significant stockholder, and repriced certain ADEC-affiliate warrants to $1.50 per share. The warrant repricing generated a $325,000 debt discount to be amortized as interest expense.
- Common shares outstanding rose to 18.54 million at quarter-end from 17.70 million at year-end, including shares issued in the Mayoly transaction. Subsequent April and May 2019 offerings raised approximately $2.50 million and $2.55 million net, respectively, and increased dilution.
- Adoption of the lease accounting standard resulted in recognition of operating lease assets and liabilities; management said adoption did not materially affect operations.
Outlook, risks, and contingencies
Management expected to complete enrollment and announce topline results from the approximately 30-patient OPTION study in summer 2019. First patients were dosed in February, and enrollment reached 50% of target in April. Management expected R&D spending to rise as candidates advanced through clinical trials, and G&A expenses to increase as the company moved closer to commercialization. These are forward-looking expectations, not reported outcomes.
The filing states that substantial doubt exists about the company’s ability to continue as a going concern. It has recurring losses and negative operating cash flows and depends on additional financing to meet obligations and fund development. The company reported that French R&D tax credits for 2016–2018 were under examination by French tax authorities; expected tax-credit receipts also affect the ADEC notes’ maturity and collateral. No legal proceedings were reported. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm issuer identity: the filing names AzurRx BioPharma, Inc., although the request identifies Gridai Technologies Corp.
- Assess current cash runway, obligations, and financing needs in light of the going-concern warning and the post-quarter offerings.
- Verify French tax-credit amounts, timing, examination status, and their effect on the pledged collateral and ADEC note maturities.
- Review the complete Mayoly agreement, including territorial royalty terms, assumed liabilities, scheduled payments, and escrowed shares.
- Reconcile the convertible-debt carrying amounts and the differing Mayoly transaction equity amounts shown in the filing’s financial statements and MD&A.
- Check subsequent clinical-trial results and enrollment against the filing’s summer 2019 outlook, and assess potential dilution from notes, warrants, options, and offerings.